MARYLAND HEIGHTS, Mo. & IRVINE, Calif.–(BUSINESS WIRE)– Masimo heeft vandaag bekendgemaakt dat Ranken Jordan Pediatric Bridge Hospital zijn monitors heeft geüpgraded naar de Radical-7 met Masimo SET® voor pule-oxymetrie.
“Ons ziekenhuis specialiseert zich in het overbruggen van de kloof tussen behandelingen in het ziekenhuis en thuiszorg voor kinderen met complexe aandoeningen, zoals hersenletsel, aangeboren afwijken of complicaties als gevolg van een vroegtijdige geboorte”, zei Laureen K. Tanner, voorzitster en ceo van Ranken Jordan Pediatric Bridge Hospital. “Doorbraaktechnologieën als deze helpen ons team bij het mogelijk maken van het onmogelijke.”
Ranken Jordan Pediatric Bridge Hospital Upgrades Their Monitors to the Radical-7 Featuring Masimo SET® Pulse Oximetry
MARYLAND HEIGHTS, Mo. & IRVINE, Calif.–(BUSINESS WIRE)– Masimo (NASDAQ: MASI) today announced that Ranken Jordan Pediatric Bridge Hospital has upgraded their monitors to the Radical-7 featuring Masimo SET® pulse oximetry.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150914005482/en/
“For children with complex medical conditions such as brain injuries, congenital defects or complications due to premature birth, our hospital specializes in bridging the gap between traditional hospital treatments and going home,” said Laureen K. Tanner, RN, MSN, FACHE, President and Chief Executive Officer of Ranken Jordan Pediatric Bridge Hospital. “Breakthrough medical technology like this helps our team make the impossible possible on a daily basis.”
The Radical-7 features Masimo SET® Measure-through-Motion and Low Perfusion™ pulse oximetry, shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms.1,2 The benefits of Masimo SET® have been proven in more than 100 independent and objective studies and used on more than 100 million patients in leading hospitals. 3,4 Researchers have found that Masimo SET®, in combination with changes in clinical practice, led to a reduction in severe retinopathy of prematurity (ROP) in pre-term infants. 5 In a study of newborns, researchers have found critical congenital heart disease (CCHD) was detected 63% of the time by standard screening and 83% of the time when screening with Masimo SET® was added. 6 The Radical-7 allows hospitals the ability to upgrade their monitor with other breakthrough measurements that are only available with Masimo rainbow® technology.
“The amazing team at Ranken Jordan Pediatric Bridge Hospital has been taking care of children with complex needs for over 70 years. They are the only pediatric sub acute facility in Missouri and one of the largest in the Midwest,” stated Joe Kiani, Founder and CEO of Masimo. “Performance in challenging situations is key and we are happy that their clinical team now has access to our flagship monitor. It is our privilege to help facilities like Ranken Jordan help kids and families safely transition from the acute care hospital to home.”
About Ranken Jordan Pediatric Bridge Hospital
Ranken Jordan offers care through a 62,000 square-foot, 34-bed inpatient program and several outpatient programs, including outpatient therapy, intensive day treatment, a physiatry clinic and a comprehensive orthopedic rehabilitation clinic. The current hospital building houses ultramodern equipment and is specifically designed to entice patients to get out of their rooms and engage in daily life-centered activities. Ranken Jordan’s Community Program provides free recreational and educational programs for all kids and their families. For more information, contact us or call 314-872-6400. www.rankenjordan.org
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care – helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In the U.S., Masimo rainbow ® SET pulse CO-Oximeter instruments and sensors are indicated to provide noninvasive monitoring of arterial oxygen saturation (SpO 2) and pulse rate (PR), carboxyhemoglobin saturation (SpCO ®), methemoglobin saturation (SpMet ®), total hemoglobin concentration (g/dl SpHb), and/or respiration rate (RRa ®). The devices are not intended to replace laboratory measurements of hemoglobin and have not been cleared by FDA to detect bleeding or reduce the amount or frequency of red blood cell (RBC) transfusions. Additional information about Masimo and its products may be found at www.masimo.com. @MasimoInnovates
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo’s unique noninvasive measurement technologies, including: total hemoglobin (SpHb®) contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (” SEC“), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo.
1 Barker SJ. Anesth Analg. 2002 Oct;95(4):967-72
2 Shah N et al. J. Clin Anesth. 2012 Aug; 24(5):385-91.
3 All studies available at http://www.masimo.com/cpub/clinical-evidence.htm
4 Data on file
5 Castillo A et al. Acta Paediatr. 2011 Feb;100(2):188-92
6 de-Wahl Granelli AD et al. BMJ. 2009;338